A new hypothesis in botulin therapy for depression: Insula cortex modification

Cosio, Terenzio; Campione, Elena

doi:10.1111/dth.13008

Cited by 5 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, some studies have found that BTA also inhibits the release of cholinergic or noncholinergic neurotransmitter in smooth muscle and exocrine glands, [11][12][13] which extends the application of BTA to more areas such as scar prevention and therapy for depression. Several studies have reported that BTA can improve the facial scar quality injected in the early postoperative period.…”

Section: Discussionmentioning

confidence: 91%

Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF‐β1/Smad and ERK pathways

Yang

Zheng

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background: Hypertrophic scar is a common complication in would healing process, and how to effectively prevent and treat it has been a hot and difficult research issue.Previous studies have showed that botulinum toxin type A (BTA) has effects on the prevention and treatment of hypertrophic scar, but little is known about the specific mechanisms.Objective: This study aimed to explore the potential mechanisms of BTA on the inhibition of hypertrophic scar formation.Methods: Hypertrophic scar-derived human fibroblasts were cultured and then treated with transforming growth factor-β1 (TGF-β1) and various concentrations of BTA. Cell proliferation and viability were measured by CellTiter 96® AQueous One Solution Cell Proliferation Assay and trypan blue staining, respectively. The total amount of collagen was examined using Sirius red staining. Collagen I and Collagen III in the culture supernatant were evaluated by enzyme-linked immunosorbent assay.Reverse transcription-quantitative polymerase chain reaction and Western blot analysis were performed to detect the transcription and translation levels.Results: Our results revealed that BTA decreased the proliferation of hypertrophic scar-derived human fibroblasts. The mRNA and protein expression levels of alphasmooth muscle actin, collagen I, and collagen III induced by TGF-β1 were inhibited by BTA in a dose-dependent manner. BTA also inhibited the phosphorylation of Smad2/3 and ERK. Conclusion:BTA decreased the proliferation of fibroblasts and prevented overdeposition of ECM through the inhibition of the TGF-β1/Smad and ERK pathways. The findings of this study provide new scientific reference for the prevention and treatment of hypertrophic scar.

show abstract

Section: Discussionmentioning

confidence: 91%

Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF‐β1/Smad and ERK pathways

Yang

Zheng

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…25 Many studies have observed a close relationship between CGRP and the pathogenesis of psoriasis. [30][31][32][33][34][35][36][37][38][39][40][41] The number of nerve fibers secreting CGRP in the skin lesions of patients with psoriasis was significantly higher than in those of patients without psoriasis. 30 Additionally, the content of CGRP in the plasma of patients with psoriasis was higher than that of those without the disease.…”

Section: Effect Of Neuropeptides On Dcsmentioning

confidence: 93%

“…It can not only paralyze muscles, but also change the level of nerve factors secreted in the nervous system. 40 A study has shown that the injection of botulinum toxin B (BTX-B) can improve psoriasis-like skin lesions in IMQ-treated mice. In their experiment, the researchers found that in mice injected with BTX-B, neuron release of CGRP decreased, and the amount of CD11c+ DCs entering the skin and that of secreted IL-23 was significantly reduced.…”

Section: Effect Of Neuropeptides On Dcsmentioning

confidence: 99%

Effects of Neuropeptides on Dendritic Cells in the Pathogenesis of Psoriasis

Zhang

Zhao

Xing

et al. 2023

JIR

View full text Add to dashboard Cite

Psoriasis is an autoimmune disease that is characterized by discolored, scaled patches of skin. Clinically, it is found that psychological factors often induce or aggravate the disease. Current research suggests that the pathogenesis of psoriasis involves the nervous and immune systems. This article reviews how neuropeptides secreted by nerve fibers affect dendritic cells in psoriasis. In this review, we describe that the neuropeptides calcitonin gene-related peptide, substance P, and vasoactive intestinal peptide can act on dendritic cells and participate in the pathogenesis of psoriasis. These neuropeptides can affect the secretion of interleukin (IL)-12 and IL-23 by dendritic cells, which stimulate T helper (Th)1, Th17, and Th22 cells to produce immune responses and cause the manifestation of psoriasis. The application of neuropeptide inhibitors can improve the skin lesions of psoriasis, which has been confirmed in clinical trials. Therefore, neuroimmune response may be a new direction to develop new drug treatments and perspectives in the development of psoriasis.

show abstract

“…O conceito de propriocepção emocional e sua interrupção de acordo com os sinais proprioceptivos captados por receptores mecânicos no rosto são conduzidos ao núcleo do trigêmeo mesencéfalo e ao locus coeruleus. Através de projeções de lá, eles podem modular a atividade do córtex pré-frontal e insular, bem como da amígdala e o impacto nos processos emocionais (Finzi & Rosenthal 2016;Cosio & Campione 2019). Em um nível molecular, a injeção facial de toxina botulínica pode alterar o metabolismo dos neurotransmissores monoaminérgicos e aumentar a expressão do fator neurotrófico derivado do cérebro nas regiões do cérebro límbico (Li et al, 2019).…”

Section: Mecanismo De Açãounclassified

A toxina botulínica na estética facial e o processamento das emoções

Vieira,

Sousa

2024

RSD

View full text Add to dashboard Cite

A ação das toxinas botulínicas é resultado de sua potente capacidade de inibir a liberação de neurotransmissores. Nesse sentido, as toxinas botulínicas apresentam um amplo espectro de indicações, tanto cosméticas, quanto terapêuticas. Dessa forma, este estudo teve como objetivo realizar uma pesquisa bibliográfica sobre a utilização da toxina botulínica Tipo A (BoNT/A) na estética facial e no processamento das emoções. Para isso, foram avaliados ensaios clínicos randomizados (ECRs) que analisassem os efeitos da BoNT/A em pacientes com transtornos de humor, com ênfase na depressão. A pesquisa foi realizada nos bancos de dados PubMed, SCIELO, Web of Science e LILACS, utilizando descritores DeCS/MeSH, tendo sido incluídos os artigos publicados em português e inglês entre os anos de 2003 a 2023. Após aplicação dos critérios, 13 artigos foram selecionados para análise. No geral, a BoNT/A mostrou-se como sendo uma alternativa para melhorar significativamente os sinais faciais de depressão quando comparado ao placebo nos estudos realizados. Na maioria dos ECRs a BoNT/A foi aplicada nos músculos mímicos do terço superior do rosto, na área glabelar, a qual esteve relacionada com a melhora dos transtornos de humor com alvo no feedback facial. Assim, evidências clínicas apontam para que o manejo dos distúrbios emocionais abranja a utilização da terapia com uso da toxina botulínica.

show abstract

A new hypothesis in botulin therapy for depression: Insula cortex modification

Cited by 5 publications

References 6 publications

Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF‐β1/Smad and ERK pathways

Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF‐β1/Smad and ERK pathways

Effects of Neuropeptides on Dendritic Cells in the Pathogenesis of Psoriasis

A toxina botulínica na estética facial e o processamento das emoções

Contact Info

Product

Resources

About